Perihilar Cholangiocarcinoma and Deep Learning

### Perihilar Cholangiocarcinoma (pCCA) and Deep Learning

#### **What is Perihilar Cholangiocarcinoma (pCCA)?**

Perihilar cholangiocarcinoma (pCCA) is a type of bile duct cancer that arises near the liver's hilum, where the bile ducts exit the liver. It is the most common type of cholangiocarcinoma (bile duct cancer) and is often associated with primary sclerosing cholangitis (PSC), a chronic liver disease characterized by inflammation and scarring of the bile ducts. Unfortunately, pCCA is frequently diagnosed at a late stage, making it one of the leading causes of mortality in PSC patients. Early detection of pCCA is critical because it allows for curative treatments such as liver transplantation or surgical resection.

---

#### **What is Deep Learning?**

Deep learning is a subset of artificial intelligence (AI) and machine learning that uses neural networks with multiple layers to analyze complex datasets. A deep learning model "learns" patterns and features from raw data, such as medical images, without requiring explicit programming. It is particularly useful in image analysis, where it can identify subtle, complex patterns that may be missed by human experts.

In this study, a specific deep learning architecture called **3D DenseNet-121** was used. This is a convolutional neural network (CNN) designed to process three-dimensional (3D) medical imaging data, such as MRI scans. DenseNet-121 is known for its efficiency in feature extraction and its ability to learn hierarchical representations of the data, making it well-suited for detecting abnormalities in medical images.

---

#### **How MRI Helps Identify the Severity of PSC**

Magnetic Resonance Imaging (MRI), particularly contrast-enhanced MRI, is a non-invasive imaging technique that provides detailed visualization of the liver, bile ducts, and surrounding tissues. In patients with PSC, MRI can help identify:

1. **Bile Duct Abnormalities**: PSC causes strictures (narrowing) and dilation of bile ducts, which can be visualized on MRI.

2. **Mass Lesions**: The presence of a mass or thickening in the bile ducts may indicate cholangiocarcinoma.

3. **Liver Damage**: MRI can assess liver fibrosis, cirrhosis, or other complications of PSC.

4. **Vascular Involvement**: MRI can reveal whether cancer has invaded nearby blood vessels, which is critical for staging and treatment planning.

However, early-stage pCCA is often challenging to detect using MRI alone because the cancer may not form a distinct mass or may blend with the background fibrosis and inflammation caused by PSC. This is where deep learning can play a transformative role.

---

#### **How Deep Learning Analyzes MRI to Predict Cancer in PSC**

Deep learning models, like the 3D DenseNet-121 used in this study, analyze MRI images to detect patterns indicative of early-stage pCCA. Here's how the process works:

1. **Data Input**:

• The model is trained on a dataset of MRI images from patients with and without pCCA.
• Images are labeled based on clinical diagnoses, such as "pCCA present" or "pCCA absent."

2. **Feature Extraction**:

• The model automatically learns to identify features associated with pCCA, such as subtle changes in bile duct structure, tissue texture, or contrast enhancement patterns.
• Unlike traditional methods, the model does not require manual feature engineering by radiologists.

3. **Prediction**:

• Once trained, the model analyzes new MRI images and predicts whether pCCA is present or absent.
• The model outputs sensitivity (ability to detect true positives) and specificity (ability to avoid false positives).

4. **Performance Comparison**:

• In this study, the deep learning model significantly outperformed expert radiologists in detecting early-stage pCCA:
• **Sensitivity**: The model detected 87.9% of pCCA cases compared to 50% by radiologists.
• **Specificity**: The model had a specificity of 84.1%, slightly lower than the radiologists' 100%, but still clinically acceptable.
• **Area Under the Receiver Operating Curve (AUC)**: The model achieved an AUC of 86.0%, compared to 75.0% for radiologists.

5. **Mass-Independent Detection**:

• Even in cases where no visible mass was present (a common scenario in early-stage pCCA), the model achieved a higher sensitivity (91.6%) than radiologists (50.6%).

---

#### **Advantages of Deep Learning in pCCA Detection**

1. **Early Detection**: The model can identify subtle changes in MRI that may indicate early-stage pCCA, even before a mass is visible.

2. **Improved Sensitivity**: Fewer cases of cancer are missed compared to radiologists.

3. **Efficiency**: The model can analyze large volumes of MRI data quickly and consistently.

4. **Non-Invasive**: Deep learning enhances the diagnostic power of existing imaging techniques without requiring additional invasive procedures.

---

#### **Conclusion**

The application of deep learning, specifically the 3D DenseNet-121 model, represents a significant advancement in the detection of perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis. By leveraging MRI data, the model can detect early-stage pCCA with higher sensitivity and comparable specificity to expert radiologists. This technology has the potential to improve outcomes by enabling earlier diagnosis and timely curative interventions for PSC patients at risk of developing pCCA.